International drug control systems

Control of narcotic drugs, psychotropic substances and precursor chemicals

Vienna, March 2009
### Historical development in international treaty law in drug control

#### Current international Conventions:

<table>
<thead>
<tr>
<th>Convention</th>
<th>Year</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Convention 1961</td>
<td>1961</td>
<td>SINGLE CONVENTION on NARCOTIC DRUGS</td>
</tr>
<tr>
<td>Convention 1971</td>
<td>1971</td>
<td>CONVENTION ON PSYCHOTROPIC SUBSTANCES</td>
</tr>
<tr>
<td>Convention 1988</td>
<td>1988</td>
<td>UNITED NATIONS CONVENTION AGAINST ILLEGAL TRAFFIC IN NARCOTIC DRUGS AND PSYCHOTROPIC SUBSTANCES</td>
</tr>
</tbody>
</table>
International Narcotics Control Board
- Established by the Single Convention of 1961

I N C B

Facts and Figures:
- Elected by ECOSOC
- Independent treaty body
- 13 members; 3 nominated by WHO, 10 nominated by Governments
- Predecessors at the time of League of Nations

United Nations
International Narcotics Control Board (INCB)
Role of INCB

Overall treaty function:
- To monitor and promote treaty compliance
- To encourage dialogue with Governments

Function:
- To administer international control systems;
- To ensure balance between supply and demand;
- To endeavor, in cooperation with Governments, to prevent illicit activities.
OBJECTIVES OF THE CONTROL SYSTEM

- **Limit** the use of narcotic drugs and psychotropic substances to legitimate medical and scientific purposes
- **Ensure** that narcotic drugs and psychotropic substances are available for medical and scientific purposes
- **Two complementary, not mutually exclusive, aims** (Report of the International Narcotics Control Board for 1999, Chapter I, “Freedom from pain and suffering”)
Analyses global drug control situation

Draws attention of Governments to any weaknesses in national drug control and treaty compliance

Suggests possible improvements at both national and international levels.
Chapter I - Internationally controlled drugs and the unregulated market

Some features of unregulated markets:

- Unlicensed individuals and/or entities trade in drugs
- Licensed individuals/entities trade in drugs that they are not authorized or entitled to deal with in contravention of the applicable laws
Internationally controlled drugs and the unregulated market *(continued)*

Sources of drugs available on unregulated markets

- Thefts or unauthorized sales from licensed manufacturers, wholesalers, distributors, health-care institutions and/or health-service providers
- Expired drugs/ substandard drugs that have been recalled by the manufacturer
- Individuals who have legally obtained drugs and sell them for profit
- Counterfeit drugs
Factors driving the unregulated market

- Limited access to health-care facilities
- Cost of drugs
- Lack of public awareness
- Inadequate drug control regulations and weaknesses in enforcement
- Consumer demand for illicit drugs
Counterfeit drugs
- An estimated 25-50 per cent of the medicines used in developing countries are believed to be counterfeit.

Internet orders
- Large majority of Internet pharmacies are unlicensed and unregulated and sell internationally controlled drugs (benzodiazepines - 84%; opioids - 68%).
- Most accept prescriptions by fax (high risk of falsification).
- Risks:
  - Lack of proper medical supervision;
  - Higher price than in legal pharmacies;
  - Buyer’s medical and financial data may be compromised.
Internationally controlled drugs and the unregulated market (concluded)

Requirements of a regulatory system

- Adequate legal framework (according to WHO, drug regulation is non-existent in a significant number of countries)
- Drug regulatory authorities must assess the efficacy, safety and quality of drugs before allowing them to be imported, manufactured or marketed;
- Drug regulatory authorities must have adequate human and financial resources;
- Health-care professionals should receive training on the promotion of rational use of drugs;
- Procurement, storage, distribution and dispensing of medicines must follow strict standards to minimize the risk of such drugs being diverted into illicit channels.

UNITED NATIONS
International Narcotics Control Board (INCB)
<table>
<thead>
<tr>
<th>Control Measure</th>
<th>1961</th>
<th>1971</th>
<th>1988</th>
</tr>
</thead>
<tbody>
<tr>
<td>Licence to deal in controlled substances</td>
<td>Article 30.1.(a)</td>
<td>Article 8</td>
<td></td>
</tr>
<tr>
<td>Licence to import-export controlled substances</td>
<td>Article 31.3(a)</td>
<td>Article 8</td>
<td></td>
</tr>
<tr>
<td>Prescription requirement</td>
<td>Article 30.2.(b)(i)</td>
<td>Article 9</td>
<td></td>
</tr>
<tr>
<td>Advertisement to general public</td>
<td>Article 10</td>
<td></td>
<td>Article 10</td>
</tr>
<tr>
<td>Adequate labelling</td>
<td>Article 16.2</td>
<td></td>
<td>Article 16.2</td>
</tr>
<tr>
<td>Shipments by mail-parcels</td>
<td>Article 19</td>
<td></td>
<td>Article 19</td>
</tr>
<tr>
<td>Trade requirements (import-export authorization system)</td>
<td>Article 31.4.</td>
<td>Article 12</td>
<td></td>
</tr>
<tr>
<td>Lack of proper documentation of export</td>
<td>Article 16.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>National laws and regulations</td>
<td>Article 31.1 (a)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Estimates for narcotic drugs</td>
<td>Article 31.1 (b)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Suppress mail for illicit trafficking</td>
<td></td>
<td></td>
<td>Article 19</td>
</tr>
<tr>
<td>Prohibition of export to P.O.Box</td>
<td>Article 31.8</td>
<td>Article 12</td>
<td></td>
</tr>
<tr>
<td>Penal provisions under national law</td>
<td>Article 36.1</td>
<td>Article 22</td>
<td></td>
</tr>
</tbody>
</table>
Governments should:

- Establish a comprehensive legal framework and rigorously enforce existing legislation
- Conduct inspections (in accordance with article 15 of the 1971 Convention)
- Correctly assess requirements for narcotic drugs and psychotropic substances
- Build capacity of staff of drug regulatory authorities
- Implement effective policies to combat counterfeit drugs
Recommendations

International organizations

✓ World Health Organization (WHO) should consider studying the dynamics of the unregulated market;

✓ WHO should consider developing a guide on best practices in dealing with the unregulated market;

✓ UNODC and WHO should provide technical assistance to Member States to build capacity in drug regulatory authorities.

Private sector

✓ Pharmaceutical industry should notify drug regulatory authorities of any attempts to manufacture and distribute counterfeit drugs.
Counterfeit Medicines

- Public Health challenge
- WHO response (IMPACT)
- International collaboration (GS1, WCO, WTO, Healthcare associations, pharmaceutical industry etc...)
- Awareness raising
- Global solution
THANK YOU

More information at
www.incb.org

Hanifa REBBANI
Drug Control Officer
Psychotropics Control Section, INCB Secretariat